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Mutations in PRPS1, Which Encodes the Phosphoribosyl
Pyrophosphate Synthetase Enzyme Critical for Nucleotide
Biosynthesis, Cause Hereditary Peripheral Neuropathy with
Hearing Loss and Optic Neuropathy (CMTX5)
Hee-Jin Kim, Kwang-Min Sohn, Michael E. Shy, Karen M. Krajewski, Miok Hwang, June-Hee Park,
Sue-Yon Jang, Hong-Hee Won, Byung-Ok Choi, Sung Hwa Hong, Byoung-Joon Kim, Yeon-Lim Suh,
Chang-Seok Ki, Soo-Youn Lee, Sun-Hee Kim, and Jong-Won Kim
We have identiﬁed missense mutations at conserved amino acids in the PRPS1 gene on Xq22.3 in two families with a
syndromic form of inherited peripheral neuropathy, one of Asian and one of European descent. The disease is inherited
in an X-linked recessive manner, and the affectedmale patients invariably develop sensorineural hearing loss of prelingual
type followed by gating disturbance and visual loss. The family of European descent was reported in 1967 as having
Rosenberg-Chutorian syndrome, and recently a Korean family with the same symptom triad was identiﬁed with a novel
disease locus CMTX5 on the chromosome band Xq21.32-q24. PRPS1 (phosphoribosyl pyrophosphate synthetase 1) is an
isoform of the PRPS gene family and is ubiquitously expressed in human tissues, including cochlea. The enzymemediates
the biochemical step critical for purine metabolism and nucleotide biosynthesis. The mutations identiﬁed were E43D,
in patients with Rosenberg-Chutorian syndrome, and M115T, in the Korean patients with CMTX5. We also showed
decreased enzyme activity in patients withM115T. PRPS1 is the ﬁrst CMT gene that encodes ametabolic enzyme, shedding
a new light on the understanding of peripheral nerve-speciﬁc metabolism and also suggesting the potential of PRPS1 as
a target for drugs in prevention and treatment of peripheral neuropathy by antimetabolite therapy.
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Charcot-Marie-Tooth inherited neuropathy (CMT) repre-
sents a clinically and genetically heterogeneous group
of hereditary peripheral neuropathies characterized by
chronic motor and sensory impairment. It is one of the
most common inherited disorders of humans and is the
most common genetic cause of neuropathy, with preva-
lence of ∼1 in 2,500 people.1 Approximately 10%–20% of
CMT is inherited in an X-linked manner (CMTX). Among
the ﬁve known loci for CMTX, the causal gene has been
identiﬁed only in CMTX1 (MIM 302800), in which the
neuropathy is caused by mutations in the gap junction
protein beta 1 gene (GJB1 [MIM 304040]) encoding the
protein connexin 32 (Cx32).2 The authors previously iden-
tiﬁed a Korean family with a syndromic form of X-linked
recessive CMT and localized the disease gene to a novel
locus for CMTX on the chromosome band Xq21.32–24
(CMTX5 [MIM 311070]).3 The male patients with CMTX5
invariably developed a unique symptom triad of hearing
loss, visual impairment, and peripheral neuropathy (table
1 and ﬁg. 1A). The hearing loss has been characterized as
sensorineural and prelingual in nature. The patients ex-
perienced progressive visual impairment from optic neu-
ropathy at ∼10 years of age and peripheral neuropathy, at
approximately the same age, that has been classiﬁed by
electrophysiology as having mixed features of segmental
demyelination and axonal loss. Follow-up of the youngest
male patient (CMTX5:IV-11), who had been reported to
have normal visual function at the time of initial presen-
tation (at age 4 years), showed that his visual function
began to be impaired at age 7 years. Pathologic exami-
nation of the sural nerve biopsy sample from the eldest
living patient (CMTX5:III-18) showed loss of both large
and small myelinated nerve ﬁbers and an increase of en-
doneurial collagen (ﬁg. 2A). Electron microscopic exam-
ination revealed segmental demyelination and remyeli-
nation with onion-bulb formation (ﬁg. 2B). The symptom
triad observed in CMTX5 was identical with that reported
in Rosenberg-Chutorian syndrome (RCS) (table 1 and ﬁg.
1B),4 and it has been speculated that CMTX5 and RCS are
allelic disorders sharing the common disease gene. As in
CMTX5, patients with RCS were not mentally retarded.
The disease locus of CMTX5 spans 15.2 cM and harbors
1170 known genes and predicted genes. Because of the
large number of positional candidate genes, we began by
evaluating those candidate genes that were known to be
expressed in the inner ear according to the cochlear ex-
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Table 1. Characteristics of Patients with CMTX5 and RCS, a Disease Allelic to CMTX5
Patient Age (in years)a/Sex
Finding (Age at Onset, in years)b
MNCV of
Median Nerve
(m/sec1) Uric Acid Levelc (Aged, in years)
Hearing
Loss
Visual
Impairment Motor
Distal
Sensory
Loss
CMTX5:III-18 28/Male  (Since infancy)  (11)  (12)  NT 4.48 (29)
CMTX5:III-21 25/Male  (Since infancy)  (13)  (12)  NT NT
CMTX5:III-24 18/Male  (Since infancy)  (8)  (12)  NT NT
CMTX5:IV-1 14/Male  (Since infancy)  (11)  (10)  51.0 3.36 (14)
CMTX5:IV-11 4/Male  (Since infancy)  (7)e  (4)  43.1 4.73 (5)
RCS:III-11 32/Male  (Since infancy)  (20)  (5)  44.8 5.43 (70)
RCS:III-13 29/Male  (Since infancy)  (19)  (2)  46.5 3.53 (68)
RCS:IV-14 3.5/Male  (Since infancy)  Nonspeciﬁc  NT NT
NOTE.—MNCV p motor nerve conduction velocity; NT p Not tested.
a Age at initial clinical evaluation and electrophysiological studies.
b  p positive ﬁnding;  p negative ﬁnding.
c Reference range, 3.40–7.20 mg/dL.
d Age at the time of blood drawing for the determination of uric acid levels.
e Follow-up examination of this patient (IV-11) showed decreased visual acuity 3 years after the initial evaluation (at age 7 years).
Figure 1. Pedigrees of the Korean family with CMTX5 (A) and the family of European descent with RCS (B). Affected male patients
are indicated by blackened boxes and the obligate carrier females by circles with central dots. The individuals whose blood was drawn
for the present study are marked with asterisks (*).
pression database (Morton cochlear expression database)5
within the locus, since sensorineural hearing loss has been
the earliest symptom and sign of both CMTX5 and RCS.
The study was approved by the Institutional Review Board
of the Samsung Medical Center, and written informed
consent was obtained from all adult subjects and from
parents on behalf of their children. Blood samples were
collected and genomic DNA was isolated from peripheral
blood leukocytes by use of the Wizard genomic DNA pu-
riﬁcation kit, according to the manufacturer’s instructions
(Promega). All coding exons and their ﬂanking intronic
sequences of the candidate genes were ampliﬁed by PCR
using the primers designed by the authors with the
Primer3 program. Cycle sequencing was performed with
the BigDye Terminator Cycle Sequencing Ready Reaction
kit (Applied Biosystems) on the ABI 3100Genetic Analyzer
(Applied Biosystems). In the course of screening the po-
sitional candidate genes, including those expressed in the
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Figure 2. Sural nerve biopsy ﬁndings of a patient with CMTX5.
A, Histological examination of the sural nerve biopsy sample re-
vealed loss of myelinated nerve ﬁbers and interstitial ﬁbrosis
(Luxol-fast blue,#400). B, Electron micrograph of the sural nerve
showed myelinated axons surrounded by concentrically arranged
cytoplasmic processes of Schwann cells forming an “onion bulb.”
The arrow indicates a remyelinating axon with an abnormally thin
myelin sheath.
inner ear (number of genes screened p 71), the authors
identiﬁed a 344TrC transition mutation in exon 3 of the
phosphoribosyl pyrophosphate synthetase gene (PRPS1
[MIM 311850; Genbank accession number NM_002764])
on Xq22.3 that generates an amino acid substitution
M115T (ﬁgs. 3 and 4A). This sequence variation was not
observed in 1,045 unrelated control chromosomes of Ko-
rean origin. On the basis of our hypothesis that the dis-
ease-causing gene would be same in CMTX5 and RCS, we
obtained DNA samples from patients and familymembers
with RCS. Direct sequencing analyses of the PRPS1 gene
revealed a 129ArC transversion mutation in exon 2 of
PRPS1 giving rise to E43D in the two clinically affected
patients with RCS and conﬁrmed the X-linked recessive
inheritance in the family (ﬁg. 4A). Again, we conﬁrmed
that E43D was not observed in 1,103 unrelated control
chromosomes of Korean origin. We also performed direct
sequencing of exon 2 and exon 3 of PRPS1 on DNA sam-
ples from 50 unrelated individuals of white origin (Coriell
Cell Repositories catalogue ID HD50CAU) and conﬁrmed
that no sequence variations were observed. The primer
sequences for the PRPS1 gene are available on request. The
mutated amino acids in the Korean patients with CMTX5
and the patients with RCS both showed perfect conser-
vation from zebraﬁsh to human (ﬁg. 4B). To further in-
vestigate the frequency of PRPS1 mutations in CMT, we
performed direct sequencing of all coding exons and exon-
intron boundary sequences of PRPS1 in 101 patients with
CMT whose previous genetic test results had ruled out
CMT1A (MIM 118220), the most common subtype of
CMT (57 male patients and 44 female patients). We ob-
served a single patient with a sequence variation in exon
4 (420GrA), which was considered to be a rare synony-
mous polymorphism (P140P) on the basis of our further
observation of its occurrence in control chromosomes
(1.1%; 2/185), and no patient had a mutation that altered
the amino acid sequence of PRPS1. This indicates, ﬁrst,
that PRPS1 is speciﬁcally mutated in CMTX5, causing the
unique symptom triad, and, second, that the gene is
highly conserved even within the human species.
PRPS1 is a ubiquitously expressed gene and is the major
isoform of the human phosphoribosyl pyrophosphate
(PRPP) synthetase gene family.6 The gene gives rise to a 2-
kb transcript and encodes 318 amino acids (including the
ﬁrst Met). The whole protein sequence of PRPS1 shows an
exceptionally high degree of conservation, with homol-
ogies 195% across different species from zebraﬁsh to hu-
man (ﬁg. 5). PRPS1 is an enzyme that catalyzes the syn-
thesis of PRPP, a substrate common to the biosynthesis
of purines and pyrimidines, from ATP and Rib-5-P (EC
2.7.6.1). To see the functional outcome of the mutation,
the authors determined the PRPS1 enzyme activity from
ﬁbroblasts obtained from skin biopsy samples from three
patients with CMTX5 (CMTX5:IV-1, IV-11, and III-18),
two nonaffected individuals in the CMTX5 family
(CMTX5:III-13 and IV-2), and two unrelated adult control
individuals (C-1 and C-2). The PRPS activity was deter-
mined as previously described.7 Brieﬂy, 100 ml of cell ex-
tract was incubated for 60 min at 37C, with 100 ml of a
pH 7.4 reaction mixture containing: TrisHCl 50 mM,
MgCl2 5 mM, EDTA 1 mM, DTT 1 mM, NaPi 32 mM,
saturating concentrations of the substrates ATP (0.5 mM)
and ribose 5-phosphate (0.15 mM), and P1 P5 diadenosine
pentaphosphate (Ap5A, an inhibitor of adenylate kinase,
0.25 mM). On completion of the incubation, the reaction
was stopped by heating at 70C, and samples were cen-
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Figure 3. The transcript map of the region on chromosome band Xq22.3 within the CMTX5 locus and the genomic structure of PRPS1
with seven coding exons. Black bars represent coding sequences, and gray bars represent UTRs. All seven coding exons of PRPS1 were
ampliﬁed and directly sequenced, according to standard procedures. The patients with CMTX5 had a missense mutation in exon 3 (blue
circle), and the patients with RCS had a missense mutation in exon 2 (red circle). Tel p telomeric; Cen p centromeric.
Figure 4. A, The chromatograms of the PRPS1 mutations detected by direct sequencing. M115T in patients with CMTX5 (left panel)
and E43D in patients with RCS (right panel). B, The affected amino acids are perfectly conserved across different species.
trifuged in Amicon cones (30,000 MW, Centricon30). To
determine the level of AMP generated from ATP, the ﬁl-
trate was injected into the high-performance liquid chro-
matography (HPLC) system with use of Waters prepacked
mBondapak C18 10-mm column and was eluted at room
temperature with 20 mM phosphate buffer (pH 2.5) at a
ﬂow rate of 1 ml/min. Nucleotide peaks were identiﬁed
by coinjection with 25 mM AMP and GMP as standard.
The instrument for HPLC and ultraviolet spectroscopywas
the Waters Breeze HPLC system, and all reagents were ob-
tained form Sigma-Aldrich. As a result, the authors ob-
served that the mutation causing CMTX5 results in a par-
tial loss of normal function, because we found decreased
PRPS enzyme activity in patients compared with unaf-
fected family members (i.e., those without the mutation)
and unrelated control individuals (ﬁg. 6).
It is of note that previous reports of missense mutations
in PRPS1 have demonstrated increased rather than de-
creased enzyme activity, with “superactive” enzymes re-
sulting in hyperuricemia and gout (MIM 311850).8,9 One
such mutation also caused sensorineural hearing loss and
developmental delay.10 We therefore measured serum uric
acid levels in patients with CMTX5 and RCS, all of whom
were shown to have normal values (table 1). No patient
with CMTX5 or RCS had been diagnosed with gout or had
other hyperuricemia-related symptoms or signs. These re-
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Figure 5. Multiple sequence alignment of PRPS1 by ClustalW,
showing the degree of conservation of the amino acid sequences
of the PRPS1 protein across different species. Homo p Homo
sapiens; Canisp Canis familiaris; Rattusp Rattus norvegicus; Mus
p Mus musculus; Danio p Danio rerio; Silurana p Silurana tro-
picalis. The reference amino acid sequences for alignment are same
as in ﬁgure 4B.
Figure 6. PRPS enzyme activity, determined by measuring the
degree of generation of AMP, the end product of PRPS enzyme, in
cultured ﬁbroblasts. The activity was decreased in patients with
CMTX5 (CMTX5:IV-1, IV-11, and III-18) compared with unaffected
family members and unrelated control individuals (CMTX5:III-13,
VI-2 and C-1, C-2).
sults are consistent with our observation that the PRPS1
activity was decreased in our patients and also demon-
strate that mutations resulting in a decreased enzymatic
activity can damage the nervous systemwithout elevating
uric acid levels. In addition, PRPS1 is considered to be
another rare example of a human disease gene in which
activating and inactivating mutations cause distinct he-
reditary disorders. Why some PRPS1 mutations cause dis-
tinct phenotypes associated with increased or decreased
enzyme activity is not known but is likely related to the
site or nature of the mutation. The functional form of the
enzyme was shown to have a hexameric structure. The
PRPS1 monomer has ﬁve-stranded parallel b sheets and
four a-helices on each of the N- and C-terminal domains,
ﬂanked by a short antiparallel b sheet protruding from the
central core (a “ﬂag” region).11 In addition to catalytic and
regulatory binding sites, PRPS1 has functional residues in-
volved in intersubunit interactions and maintaining the
stability of the enzyme. The mutation in CMTX5 occurred
at the Met 115 residue of a-helix of N-terminal domain,
and the mutation in RCS occurred at the Glu 43 residue
of the “ﬂag” region of the N-terminal domain11 (ﬁg. 7A).
It was speculated that the increased enzyme activity was
caused by mutations that alter the transmission of allo-
steric effects on the active sites of PRPS1, resulting in de-
creased inhibition.8 Intriguingly, the PRPS1 mutations
causing decreased enzyme activity (CMTX5 and RCS)were
occurring in the interface between the A and D subunits,
whereas those causing increased enzyme activity were
found in the interface between the A and C subunits, in-
dicating that the different regulatory behaviors of muta-
tions are from altered interactions between subunits (ﬁg.
7B and S. Larsen, personal communication11).
Lastly, acquired peripheral neuropathy from antimeta-
bolitemedications is one of themajor side effects of cancer
chemotherapy and of other medications, such as statins
and nucleoside reverse transcriptase inhibitors utilized to
treat patients with HIV (drug-/chemotherapy-induced pe-
ripheral neuropathy).12,13 Some of these medications also
cause sensorineural hearing loss and optic neuropathy, as
in the patients with CMTX5 and RCS. Several agents have
been developed for potential use as chemoprotectants to
reduce these side effects, but none have proven effective.14
As the metabolic enzyme critical for nucleotide biosyn-
thesis, our ﬁndings provide a clue to the pathophysiology
of acquired form of peripheral neuropathy and also raise
the potential of the PRPS1 gene as a therapeutic target to
prevent or treat medication-induced acquired peripheral
neuropathy, sensorineural hearing loss, and/or optic
neuropathy.14,15 Indeed, the PRPS1 gene, along with other
PRPS family genes, has been included in the part of the
human genome thought to offer opportunities for drug
therapy.16
In summary, we found that missense mutations in the
PRPS1 gene cause a syndromic form of peripheral neu-
ropathy associated with sensorineural hearing loss and op-
tic neuropathy with the help of the cochlear expression
database. This is the ﬁrst report of inherited peripheral
neuropathy from decreased activity of a metabolic en-
zyme critical for purine metabolism and nucleotide bio-
synthesis, shedding a new light on the understanding of
peripheral nerve-speciﬁc metabolism and the pathophys-
iology of antimetabolite-induced acquired peripheral
neuropathy.
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Figure 7. A, The locations of the mutations on the ribbon diagram of the PRPS1 monomer.11 M115T in CMTX5 on the a-helix of N-
terminal domain (blue) and E43D in RCS on the “ﬂag” region of the N-terminal domain (green). B, Hexameric structure and subunits
of PRPS1. Reprinted with permission from Nature Publishing Group.11
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